CMN-009 / CoImmune, Memorial Sloan-Kettering Cancer Center - LARVOL DELTA

CoImmune Obtains License to Target DLL3 with IL-18 Armored CAR Technology (PRNewswire) - "CoImmune, Inc...announced it has exercised its option to obtain an exclusive license in the Delta-like Ligand 3 (DLL3)-targeted, allogeneic Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell therapy field to interleukin-18 (IL-18) Armored CAR technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company is coupling the technology with allogeneic CIK cells and launched a development program focused on solid tumors with initial trials planned in small cell lung cancer (SCLC)....'IL-18 expression has the potential to greatly enhance the potency of DLL3-targeted therapy and we look forward to advancing our development of CMN-009, an IL-18 armored anti-DLL3 CAR-CIK therapeutic for SCLC'....CoImmune's IL-18 armored CARCIK-DLL3 product prototype, CMN-009, will be studied in animal models throughout the remainder of 2023....The Company expects to initiate IND-enabling studies in the first half of 2024."

Licensing / partnership • Preclinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor